Dr. Shain Discusses Emerging Agents in Multiple Myeloma

Video

In Partnership With:

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.

Oprozomib, an oral agent, is an irreversible proteasome inhibitor that has shown good activity in highly refractory patients.

Additionally, there is marizomib, another proteasome inhibitor that is being looked at alone and in combinations. It still requires further study—but it is something exciting that is on the horizon, says Shain.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Related Content
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article
Andrew Kuykendall, MD

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

October 16th 2023
Podcast
Paul G. Richardson, MD, of Dana-Farber Cancer Institute

Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma

April 18th 2024
Article
Paul G. Richardson, MD

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023
Podcast
Sundar Jagannath, MBBS, of Tisch Cancer Institute, Mount Sinai

Linvoseltamab Elicits Deep Responses in Late-Stage R/R Multiple Myeloma

April 8th 2024
Article
The FDA has approved ciltacabtagene autoleucel (Carvykti; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide (Revlimid).

FDA Approves Cilta-Cel for R/R Multiple Myeloma After at Least One Prior Line of Therapy

April 6th 2024
Article